Immunomodulatory effects of dihydroartemisinin have been identified, including its ability to reduce lupus-associated nephritis by inhibiting the production of anti-dsDNA antibodies, reducing TNF-α secretion, and blocking NF-κB signaling [10]. The gene discussed is NFKB1; the disease is systemic lupus erythematosus.